Evidence map›Paper›PMID 42564586›Full record

ArticleJournal of orthopaedic translation2026

Intra-articular delivery of VEGF targeting miR-126-3p and miR-140-5p ameliorates synovitis and pain in a rat model of post-traumatic knee osteoarthritis.

Tatsumi Tanaka, Eriko Toyoda, Makoto Ogawa, Ryoka Uchiyama, Miyu Tamaki, Masahiko Watanabe, Masato Sato

Abstract read
In one paragraph

Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tatsumi TanakaDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Eriko ToyodaDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Makoto OgawaDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Ryoka UchiyamaDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Miyu TamakiDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Masahiko WatanabeDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Masato SatoDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/objective: Knee osteoarthritis (KOA) is the most common joint disorder and causes pain and functional limitation. Patients who are refractory to conservative treatment or unsuitable for surgery owing to advanced age or comorbidities have limited options. Vascular endothelial growth factor (VEGF) is implicated in synovitis, angiogenesis and pain in KOA. microRNA (miRNA) based therapies have recently attracted attentions. This study aimed to investigate whether intra-articular delivery of VEGF-targeting miRNA can reduce synovitis and pain. Methods: Human synovial sarcoma cell line HS-SY-II was used for screening of VEGF-targeting miRNAs and primary synovial fibroblasts derived from KOA patients was used for confirmation of the efficacy. miRNA mimics were transfected and VEGF production was quantified. Results: Combination of miR-126-3p and miR-140-5p suppressed VEGF production in HS-SY-II cells than either miRNA alone and the suppressive activity on VEGF production was confirmed in primary synovial fibroblasts from KOA patients. In ACLT rats, synovial VEGF levels were increased in NC group compared with normal rats and tended to be lower in all miRNA-treated groups. Hindlimb weight-bearing ratios were reduced to about 30% after ACLT and remained low in the NC group, whereas they gradually improved in the miR-126-3p and miR-140-5p monotherapy groups and almost recovered in the miR-Mix group. At final time point, weight-bearing ratio was significantly higher in miR-Mix group than NC group. Histologically, Krenn scores were tend to lower in miR-126-3p and miR-Mix groups than NC group, indicating amelioration of synovitis, whereas OARSI histopathology scores for femoral cartilage did not differ significantly among groups and tended to be higher in miR-treated groups. There was a strong negative correlation between Krenn synovitis score and hindlimb weight-bearing ratio (Spearman's ρ = -0.7, Conclusion: Intra-articular administration of VEGF-suppressive miR-Mix ameliorated synovitis and pain-related behaviour. In highly unstable traumatic model, however, structural protection of articular cartilage was not observed and cartilage degeneration even tended to be worse in miR-treated groups, possibly due to increased weight-bearing following pain relief. The translational potential of this article: These findings suggest intra-articular delivery of VEGF-suppresive miRNAs may represent novel analgesic strategies for KOA by reducing synovitis within joint. miRNA-based modulation of VEGF production could potentially be translated into future disease-modifying and analgesic treatments, however further studies using non-traumatic KOA models, safety evaluation and clarifying molecular mechanisms are required.

Indexed as

Intra-articular injectionsKnee painmicroRNAsOsteoarthritisSynovitisVascular endothelial growth factor A

Identifiers

PMID42564586
PMCPMC13444623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.